– KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms –CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat.
- KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. ET.
A live webcast of the presentation will be available on the Company s website at www.kalvista.com. An audio archive will be available on KalVista s website for 30 days following the presentations.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially ta
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
th C1-Inhibitor Deficiency Angioedema Workshop, which will be held virtually from June 3-6, 2021.
The presentation details are as follows:
Title: Fast improvement of hereditary angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phase 2 cross-over trial in patients with HAE type I and II
Session Date and Time: Saturday, June 5, 2021, 9:45 a.m. CEST
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K Audhya, MD, MBA as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.